跳至主要内容
临床试验/NCT01687374
NCT01687374Unknown4 期

Phase IV Study of the Effect of Parathyroid Hormone on Fractures of the Humerus

Hvidovre University Hospital1 个研究点 分布在 1 个国家目标入组 72 人开始时间: 2012年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
72
试验地点
1
主要终点
Changes in constant score

研究概览

简要总结

Hypothesis:

The investigators want to study whether parathyroid hormone improves healing of humerus after a fracture. The investigators will assess healing of the humerus with Constant score.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
65 Years 至 85 Years(Older Adult)
性别
All
接受健康志愿者

入选标准

  • proximal humeral fracture eligible for conservative treatment.
  • able to understand the protocol
  • signs an informed consent

排除标准

  • liver disease
  • kidney disease
  • severe osteoporosis
  • malignant disease
  • bone metabolic disease
  • oral treatment with bisphosphonates during the last 3 months.
  • treatment with Denosumab during the last 6 months.
  • intravenous treatment with bisphosphonates during the last 12 months.

研究组 & 干预措施

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

Parathyroid hormone

Experimental

干预措施: 1-84 parathyroid hormone (Drug)

结局指标

主要结局

Changes in constant score

时间窗: 5, 8, 11, 23, and 104 weeks.

Constant score summarizes the function of the arm using a questionnaire (activities of daily living - ADL) and functional testing of the arm.

次要结局

  • Changes in Oxford Shoulder Score(5, 8, 11, 23, and 104 weeks.)
  • Changes in bone formation evaluated by X-ray.(5, 8, 11, 23, and 104 weeks.)
  • Changes in biochemical bone markers(0, 5, 25 weeks)
  • Changes in regulatory T lymphocytes(0, 8, 24 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ulrich Bang

Principal investigator

Hvidovre University Hospital

研究点 (1)

Loading locations...

相似试验